- Home
- ELAB vs LABT Comparison
ELAB vs LABT Comparison
Compare ELAB & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | LABT |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.3M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | ELAB | LABT |
|---|---|---|
| Price | $4.57 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 333.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.66 |
| 52 Week High | $15.00 | $6.85 |
Technical Indicators
Market Signals| Indicator | ELAB | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 39.04 |
| Support Level | $4.40 | N/A |
| Resistance Level | $5.14 | $2.50 |
| Average True Range (ATR) | 0.34 | 0.23 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 31.56 | 6.12 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.